ストックスクリーナーアプリを入手
31.49
0.03%
-0.01
アフターアワーズ：
31.45
-0.04
-0.13%
Catalyst Pharmaceuticals Inc (CPRX) 最新ニュース
Catalyst Pharmaceuticals (CPRX) Stock Looks Fairly Valued After Phase 1 Agamree Data - Sahm
Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1bn - Investing.com
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data - TradingView
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Deep Value Play with Rare Disease Pipeline Strength - ChartMill
CPRXCatalyst Pharmaceuticals Inc Earnings - Finviz
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE® - Yahoo Finance
Vamorolone Phase 1 results at Catalyst (NASDAQ: CPRX) show activity without key immunosuppression - Stock Titan
Catalyst reports Phase 1 vamorolone study results - Investing.com
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses - The Manila Times
Catalyst's rare-disease steroid showed immune activity without the usual suppression - Stock Titan
Monolithic Power Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Monolithic Power Systems, Inc.MPWR - Business Wire
Skeletal Nickel Catalyst Market Growth to Accelerate by 2035 Amid Rising Pharma DemandNews and Statistics - IndexBox
Acadia Pharmaceuticals (ACAD) Gets 90-Day Catalyst Watch from Ci - GuruFocus
Quantified Common Ground Fund's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Catalyst Pharmaceuticals (CPRX) Following Strong Rare Disease Results Is The Upside Already Priced In - Sahm
Shuttle Pharmaceuticals (NASDAQ:SHPH) surges; Dogecoin miner news sends volume up 70x - TechStock²
Price to earnings forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Price to sales forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Enterprise value to revenue forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Price to book forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Enterprise value to EBIT forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Enterprise value to EBITDA forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Understanding the Setup: (CPRX) and Scalable Risk - Stock Traders Daily
Catalyst Pharmaceuticals (CPRX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Nationwide Renaissance Small Cap Growth Fund's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Catalyst Pharmaceuticals stock edges higher to 31.41 after patient summit event, CatalystForRare - Traders Union
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc.CPRX - Business Wire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Passes "Caviar Cruise" Quality Screen with Zero Debt and 147.5% ROIC - ChartMill
Catalyst Pharmaceuticals (CPRX) Gets Early FTC Clearance For Angelini Merger - Sahm
Catalyst Pharmaceuticals to Be Acquired by Angelini Pharma in All-Cash Merger – Key Details from 8-K Filing - Minichart
Catalyst Pharma Gains FTC Clearance for Angelini Merger - TipRanks
Catalyst Pharmaceuticals merger cleared HSR waiting period as closing targets Q3 2026 - TradingView
HSR waiting period ends for Catalyst (NASDAQ: CPRX) and Angelini Pharma merger - Stock Titan
Catalyst Pharmaceuticals consensus steadies, Hold rating frames CPRX shares - AD HOC NEWS
Catalyst Pharmaceuticals Inc (CPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Catalyst Pharmaceuticals Inc - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SMID Core Equity Portfolio's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Catalyst Pharmaceuticals Inc (CPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Institutional Confidence - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
The Technical Signals Behind (CPRX) That Institutions Follow - Stock Traders Daily
Angelini Pharma to buy Catalyst in deal worth $4.1 billion - MSN
HC Wainwright & Co. Downgrades Catalyst Pharmaceuticals (CPRX) - MSN
Catalyst Investor Sues Over Proposed $4.1B Angelini Buyout - Law360
Catalyst (CPRX) up 0.6% since last earnings report: Can it continue? - MSN
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Angelini Pharma to buy Catalyst (CPRX) for $31.50 per share; virtual vote July 8 - Stock Titan
Catalyst Pharmaceuticals | DEFM14A: Definitive proxy statement relating to merger or acquisition - Moomoo
Catalyst Pharmaceuticals (CPRX) CMO gets 3,052 shares, 743 withheld for tax - Stock Titan
Dakota Review Highlights Broad-Based Strength in May 2026 Private Markets Activity - TipRanks
Homogeneous Catalyst Market Growth Outlook to 2035: Trends, Drivers, and Regional AnalysisNews and Statistics - IndexBox
Precision Trading with Catalyst Pharmaceuticals Inc. (CPRX) Risk Zones - Stock Traders Daily
CPRX PE Ratio & Valuation, Is CPRX Overvalued - Intellectia AI
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer - news.financial
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
D.R. Horton Inc. (DHI) Q1 2026 Earnings: Slight EPS Beat Amid Mixed Housing ConditionsEarnings Growth Analysis - thelegaladvocate.com
H.C. Wainwright Maintains Catalyst Pharmaceuticals(CPRX.US) With Hold Rating, Maintains Target Price $31.5 - Moomoo
Atea PharmaceuticalsI'm Optimistic Ahead Of Critical HPV Catalyst (NASDAQ:AVIR) - Seeking Alpha
Catalyst (CPRX) to be acquired by Angelini Pharma for $31.50 per share (cash) - Stock Titan
H.C. Wainwright Downgrades Catalyst Pharmaceuticals(CPRX.US) to Hold Rating, Cuts Target Price to $31.5 - Moomoo
Catalyst Pharmaceuticals | PREM14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term - Yahoo Finance
CPRX Technical Analysis | Trend, Signals & Chart Patterns | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):